Harrow, Inc. (HROW)

NGM – Real vaqt narxi. Valyuta: USD

39.96

+0.54 (1.37%)

Bozor ochiq: Aug 12, 2026, 2:56 PM EDT

39.94

+0.52 (1.32%)

Oldingi bozordan keyin: Aug 11, 2026, 7:59 PM EDT

11.08.2026

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

11.08.2026

Harrow Q2 Earnings Call Highlights

Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.

11.08.2026

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.

06.08.2026

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Harrow, Inc. (HROW)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Harrow, Inc. (HROW)

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow Q2 Earnings Call Highlights

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Videolar

No Data

Press-relizlar

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow Q2 Earnings Call Highlights

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Videolar

No Data

Press-relizlar

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Search stocks

Harrow, Inc. (HROW)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Harrow, Inc. (HROW)

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow Q2 Earnings Call Highlights

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Videolar

No Data

Press-relizlar

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow Q2 Earnings Call Highlights

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Videolar

No Data

Press-relizlar

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease